Erythroid-predominant myelodysplastic syndromes: Enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification

Modern Pathology

Volumn 21, Issue 11, 2008, Pages 1394-1402

  Wang, Sa A ^a,b,f   Tang, Guilin ^a   Fadare, Oluwole ^c   Hao, Suyang ^a   Raza, Azra ^d   Woda, Bruce A ^a   Hasserjian, Robert P ^e  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c WILFORD HALL MEDICAL CENTER   (United States)

^d ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f Department of Hematopathology ^*  (United States)

Author keywords

Blasts enumeration; Erythroid precursors; Myelodysplastic syndrome; Prognosis; Survival

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; ERYTHROID PRECURSOR CELL; ERYTHROID PREDOMINANT MYELODYSPLASTIC SYNDROME; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CELL COUNT; ERYTHROBLASTS; ERYTHROID PRECURSOR CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 57749117216     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.142     Document Type: Article

References (28)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-458.
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-625.
3. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
4. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-3674.
5. de Witte T, Brand R, van Biezen A, et al. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. Haematologica 2006;91:750-756.
6. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579-585.
7. Santini V, Gozzini A, Bosi A. Treatment options in myelodysplastic syndromes: a new frontier. J Chemother 2008;20:291-296.
8. Nakai K, Kanda Y, Fukuhara S, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 2005;19:396-401.
9. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-1803.
10. Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006;106:112-119.
11. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266-1269.
12. Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007;109:4158-4163.
13. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727-736.
14. Bennett JM. A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol 2005;32:S3-S10.
15. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
16. Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000;24:983-992.
17. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-7603.
18. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
19. Mitelman F. An International System for Human Cytogenetic Nomenclature (1995), Vol. 1995. Karger: Basel; Farmington, CT, 1995.
20. Mazzella FM, Smith D, Horn P, et al. Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients. Am J Hematol 2006;81:484-491.
21. Lee YT, Miller LD, Gubin AN, et al. Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays. Blood 2001;98:1914-1921.
22. Park S, Picard F, Dreyfus F. Erythroleukemia: a need for a new definition. Leukemia 2002;16:1399-1401.
23. Park S, Picard F, Guesnu M, et al. Erythroleukaemia and RAEB-t: a same disease? Leukemia 2004;18:888-890.
24. Olopade OI, Thangavelu M, Larson RA, et al. Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood 1992;80:2873-2882.
25. Hofmann WK, de Vos S, Komor M, et al. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002;100:3553-3560.
26. Pellagatti A, Esoof N, Watkins F, et al. Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. Br J Haematol 2004;125:576-583.
27. Pellagatti A, Cazzola M, Giagounidis AA, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006;108:337-345.
28. Park S, Picard F, Azgui Z, et al. Erythroleukemia: a comparison between the previous FAB approach and the WHO classification. Leuk Res 2002;26:423-429.